Corbus Pharmaceuticals Holdings, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-07.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2023-03-07
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $881.71K, a 77.61% decline from fiscal 2020.
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $3.94M, a 89.11% decline from fiscal 2019.
- Corbus Pharmaceuticals Holdings, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $36.14M, a 649.51% increase from fiscal 2018.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 derived: sum of 3 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-07 |
| 2022-06-30 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 derived: sum of 3 quarters · filed 2023-03-07 | $97.32K derived: sum of 4 quarters · filed 2023-03-07 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $97.32K derived: sum of 3 quarters · filed 2023-03-07 | $233.88K derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $97.32K derived: sum of 2 quarters · filed 2023-03-07 | $233.88K derived: sum of 3 quarters · filed 2023-03-07 | $881.71K 10-K · filed 2023-03-07 |
| 2021-09-30 | $97.32K 10-Q · filed 2022-11-08 | $233.88K derived: sum of 2 quarters · filed 2022-11-08 | $881.71K 10-Q · filed 2022-11-08 | $1.54M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $136.56K 10-Q · filed 2022-08-09 | $784.38K 10-Q · filed 2022-08-09 | $1.44M derived: sum of 3 quarters · filed 2022-08-09 | $2.67M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $647.82K 10-Q · filed 2022-05-10 | $1.31M derived: sum of 2 quarters · filed 2022-05-10 | $2.54M derived: sum of 3 quarters · filed 2022-05-10 | $2.82M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $658.20K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.89M derived: sum of 2 quarters · filed 2022-03-08 | $2.18M derived: sum of 3 quarters · filed 2022-03-08 | $3.94M 10-K · filed 2022-03-08 |
| 2020-09-30 | $1.23M 10-Q · filed 2021-11-12 | $1.52M derived: sum of 2 quarters · filed 2021-11-12 | $3.28M 10-Q · filed 2021-11-12 | $5.85M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $286.35K 10-Q · filed 2021-08-12 | $2.05M 10-Q · filed 2021-08-12 | $4.62M derived: sum of 3 quarters · filed 2021-08-12 | $7.21M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.76M 10-Q · filed 2021-05-13 | $4.34M derived: sum of 2 quarters · filed 2021-05-13 | $6.93M derived: sum of 3 quarters · filed 2021-05-13 | $36.02M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $5.16M derived: sum of 2 quarters · filed 2021-03-15 | $34.26M derived: sum of 3 quarters · filed 2021-03-15 | $36.14M 10-K · filed 2021-03-15 |
| 2019-09-30 | $2.59M 10-Q · filed 2020-11-09 | $31.68M derived: sum of 2 quarters · filed 2020-11-09 | $33.57M 10-Q · filed 2020-11-09 | $35.50M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $29.09M 10-Q/A · filed 2020-08-31 | $30.98M 10-Q/A · filed 2020-08-31 | $32.91M derived: sum of 3 quarters · filed 2020-08-31 | $34.00M derived: sum of 4 quarters · filed 2020-08-31 |
| 2019-03-31 | $1.89M 10-Q · filed 2020-05-11 | $3.81M derived: sum of 2 quarters · filed 2020-05-11 | $4.90M derived: sum of 3 quarters · filed 2020-05-11 | $5.76M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $3.02M derived: sum of 2 quarters · filed 2020-03-16 | $3.87M derived: sum of 3 quarters · filed 2020-03-16 | $4.82M 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.09M 10-Q · filed 2019-11-07 | $1.94M derived: sum of 2 quarters · filed 2019-11-07 | $2.89M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $853.65K 10-Q · filed 2019-08-08 | $1.80M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |